Zyvox Medicare “Add-On” Payments Denied; CMS Wary Of Precedent
Executive Summary
The denial of Medicare "add-on" payments for Pharmacia's Zyvox reflects CMS' desire to avoid a precedent that could make numerous older therapies eligible for enhanced reimbursement, the agency said in an Aug. 1 final rule implementing changes to the hospital in-patient payment system
You may also be interested in...
Guilford Gliadel Denied Add-On Payments By CMS; New IL-2 Code Proposed
Guilford's Gliadel Wafer does not warrant add-on payments because the product's cost is already reflected in DRG weights, CMS says
Guilford Gliadel Denied Add-On Payments By CMS; New IL-2 Code Proposed
Guilford's Gliadel Wafer does not warrant add-on payments because the product's cost is already reflected in DRG weights, CMS says
Xigris Medicare “Add-On” Payments Approved; CMS Estimates 50,000 Cases
The Centers for Medicare & Medicaid Services is estimating that the Medicare market for Lilly's Xigris will be $340 mil. in fiscal year 2003
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: